Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip?

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Lilly Cuts Low-Dose Zepbound Price Up to 20% for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

Eli Lilly cuts Zepbound price to widen access for obesity drug

Eli Lilly said it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more ...

Where will Eli Lilly be in 10 years?

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). The company overtook early GLP-1 leader Novo Nordisk. Eli Lilly is increasingly reliant on its GLP-1 drugs.

A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...